imagen1 imagen3 imagen2 imagen3 imagen1 imagen2 imagen3 imagen1 imagen2
"... for us research is already more than a vocation, it is a commitment, that we renew everyday"

Dr. Jordi Monés, the director

Dr. Jordi Monés, the director

Dr. Jordi Monés is an ophthalmologist specialised in diseases of macula, retina and vitreous humour. Graduated in Medicine and Surgery by University of Barcelona, he subsequently specialized in Ophthalmology via MIR at Centro de Oftalmología...

The IMIR

Centro TEKNON

The Institut de la Macula i de la Retina (IMIR) is a center devoted solely to the treatment and research of the macular, retinal and vitreous medical and surgical conditions. Special dedication to clinical research with Clinical Trials in Phase I,II,...
Siguenos... Institut Macula en Facebook  Institut Macula en twitter  Institut Macula en youtube

Jordi Monés presents the future treatment of retinal vein occlusion at the Ophthalmological World Congress in Abu Dhabi
Feb 20, 2012.- The Director of IMIR and the Barcelona Macula Foundation, Jordi Monés, was guest speaker at the World Congress Ophthalmological held this past weekend in Abu Dhabi. There has...
Embryonic stem cells reach the first patients
COMPANY NEWS: Jan 24th 2012. The IMIR and Dr. Jordi Monés, cited in an article in La Vanguardia on embryonic stem cells and AMD related to the publication of a scientific...
Research and Innovation are key factors in combating degenerative diseases in the eye
Jan 17th 2012 - The Breakfast La Salle celebrated this morning was focused on research and innovation as a key factor in combating degenerative diseases in the eye. The conference was led by Dr. Jordi Monés,...
The Camp Nou smokeless initiative, awarded by the semFYC
Jan 16th 2012 - RELATED NEWS. The Spanish Society of Family Medicine and Community(semFYC) has awarded FC Barcelona for the decision to bansmoking in the Camp Nou stadium and turn in a smoke-free.The semFYC, a...

  Pathologies

Publications

Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to pathological myopia: 6-month results L....
Delay in treating age-related macular degeneration in Spain is associated with progressive vision lossConclussions Delayed...
Management of diabetic macular edema with antiangiogenic therapyEvaluation of: Chun DW. Heier JS. Topping TM, Duker JS, Bankert...

Conferences

02. Symposium “A NEW VISION OF AMD” Dr. Jordi Monés: Efficacy 83rd Congress of the Spanish Society of...
03. Clinical-update in AMD Directors: Jordi Monés i Carilla, Francisco Gómez-Ulla de Irazazábal Level:...
04. Mystery Case. Fluorescein cases in 2007. The Macula Society. June 2007, London

  Ensayos Clínicos

Multicenter study OPH 1001 - Research Coordinator

Multicenter study OPH 1001 - Research Coordinator
2010 - Research Coordinator of the 8 research centers in the multicenter study in Spain:A phase 2, randomized, double-masked,...

Phase 1 Study of ARC 1905 -Principal investigator and protocol...

Phase 1 Study of ARC 1905  -Principal investigator and protocol co-designer
2009 -Principal investigator and protocol co-designer - A phase 1 study to establish the safety and tolerability of ARC 1905...

Video


Research & Innovation, key factors in combating degenerative diseases of the eye
Summary of presentation "R & I, a key factor in combating degenerative diseases of the eye" by Dr. Jordi Monés. The founder of the Barcelona Macula Foundation has participated as invited to breakfast at La Salle on 17 January...
Institut Macula Retina
To prevent macular degeneration, early detection is important, consistency in treatment and research.
The Pathophysiology of Wet AMD - by Genentech
Ranibizumab: the approved Anti-VEGF therapy for wet AMD, diabetic macular edema and retinal vein oclusion
Retina
Retina
Macular Degeneration Description
Macular Degeneration Description
Macular Degeneration Symptoms
Macular Degeneration Symptoms
Macular Degeneration Wet Form
Macular Degeneration Wet Form
Macular Edema
Macular Edema
Retinal Tear
Retinal Tear